November 2024 – Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, shares new insights into the global clinical trial landscape for Diffuse Large B-Cell Lymphoma (DLBCL), further reinforcing its leadership in oncology research.
DLBCL is the most prevalent and aggressive subtype of non-Hodgkin lymphoma (NHL), accounting for 30-40% of cases worldwide. Its heterogeneity, characterized by key subtypes like Germinal Center B-cell (GCB) and Activated B-cell (ABC), poses significant challenges in treatment. Novotech’s latest analysis highlights these complexities while highlighting ongoing advancements in therapeutic strategies to address this aggressive disease.
Key Insights from DLBCL Clinical Trials
Since 2019, more than 1,500 clinical trials for DLBCL have been initiated globally, indicating strong research momentum:
- Asia-Pacific: Leads with 41% of trials, driven largely by China’s clinical research activity.
- North America: Accounts for 33% of trials, with the United States leading in trial volume.
- Europe: Represents 19% of trials, focusing on both hematological and solid tumor research.
These findings highlight the global effort to improve treatment options for DLBCL patients.
Advances in DLBCL Treatment
Novotech’s report also highlights breakthroughs in DLBCL treatment, moving beyond traditional chemotherapy to explore new therapeutic options:
- Targeted therapies: Phase III trials for Mosunetuzumab and Selinexor are showing promise, particularly for relapsed or refractory DLBCL patients.
- Immunotherapies: Novotech is involved in the development of CAR T-cell therapies, checkpoint inhibitors, and bispecific antibodies, which have shown strong efficacy in high-risk DLBCL patients who do not respond to standard treatments like R-CHOP.
Ongoing efforts to personalize DLBCL treatment through genomic profiling and molecular diagnostics are expected to yield more precise and effective treatment strategies. In combination with innovative therapies such as EZH2 inhibitors targeting GCB subtypes and novel agents addressing the ABC subtype, these approaches are advancing more tailored and successful interventions.
Download the Full Report
For detailed analysis of the DLBCL clinical trial landscape, including emerging treatment strategies and global trial trends, download Novotech’s latest DLBCL Global Clinical Trial Landscape Report.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.
Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit: https://novotech-cro.com/talk-to-an-expert